Introduction
============

Cystic fibrosis (CF) is a severe life-shortening multiorgan disease caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR) chloride channel, which plays a fundamental role in salt and fluid transport across the surfaces and ducts of many epithelial organs including the lungs, pancreas, and gastro-intestinal tract. In patients with CF, CFTR dysfunction results in impaired epithelial ion and water transport that leads to a characteristic multi-organ pathology ([@B50]). More, than 2000 *CFTR* variants have been identified in CF patients, with F508del being the most common accounting for 70% of all CF mutations ([@B64]). Disease-causing mutations may lead to various molecular defects in CFTR protein production, processing, channel function, and stability at the plasma membrane ([@B70]; [@B50]). Drug development efforts aiming to restore CFTR function have yielded mutation specific pharmacotherapies that are now available for a subgroup of patients with CF ([@B29]). These include the CFTR potentiator compound ivacaftor (VX-770) that can improve channel activity in CFTR gating mutations present in ∼5% of CF patients and the combination of ivacaftor with the CFTR corrector compound lumacaftor (VX-809) that has been approved for F508del homozygous patients ([@B56]). The large number of disease-causing variants and the variability of biological effects of CFTR mutations and their responsiveness to CFTR modulator therapies argues that targeting an alternative chloride channel may be an attractive therapeutic strategy in CF ([@B39]). Emerging evidence suggests that the alternative chloride channel SLC26A9 is a modulator of CFTR function and a potential candidate to circumvent the primary ion transport defect in several organs affected by CF including the lungs, the pancreas, and the gastro-intestinal tract independent of the *CFTR* genotype ([@B39]; [@B29]). In this review, we summarize the basic physiological and pharmacological properties of SLC26A9, outline its regulation and molecular interaction with CFTR, detail the role of SLC26A9 as a disease modifier in CF and potentially in other diseases, and finally discuss the impact of these discoveries on future research that is needed to explore this alternative chloride channel as a potential therapeutic target in the clinical arena.

Physiology, Pharmacology, and Regulation of SLC26A9
===================================================

SLC26A9 is a member of the solute-linked carrier 26 (SLC26) anion transporter family that functions uniquely as a chloride channel with minimal conductance to bicarbonate ([@B27]; [@B46]). SLC26A9 is mainly expressed in epithelial cells of the respiratory tract, stomach, duodenum, ileum, and the pancreas, while transcripts were also detected in the salivary gland, kidney, brain, heart, prostate, testis, ovary, and skin ([@B44]; [@B73]; [@B19]; [@B38]; [@B43]; [@B22]). SLC26 members share a conserved structural organization: N-terminally the SLC26/sulphate permease transmembrane domain and C-terminally the cytoplasmic sulphate transporter and anti-sigma factor antagonist (STAS) domain ([@B28]). The STAS domain plays a role in membrane targeting, interaction with scaffolding proteins and other ion channels (detailed later). Furthermore, structural variants in the STAS domain were reported to associate with diseases linked to SLC26 transporters ([@B61]). SLC26A9 also has a type-I PDZ-binding domain at the C-terminus (T-A-L), which may promote vesicular trafficking or assembly of macromolecular complexes as seen in other SLC26 members ([@B45]; [@B58]). The human SLC26A9 transcript is alternatively spliced, such that inclusion of an exon results in a 96 amino acid extension at the C-terminus (isoform 2). The shorter splice form of 791 residues was designated as canonical isoform, which was also mainly used in heterologous expression systems; however, the isoform-ratio in specific tissues has not yet been elucidated. Similarly to the glycosylation pattern of CFTR, SLC26A9 also displays both core- and complex N-glycosylated forms, which may be important for plasma membrane targeting or function ([@B40]; [@B60]; [@B68]; [@B11]).

The function of SLC26A9 has been widely investigated in heterologous expression systems. Whole-cell patch clamp studies showed that SLC26A9 is a constitutively active chloride channel displaying linear current--voltage characteristics ([@B27]; [@B46]; [@B12]; [@B5]; [@B60]), while the current amplitude was not affected by cAMP stimulation or increase in intracellular Ca^2+^ ([@B12]; [@B60]). Interestingly, SLC26A9-expressing epithelial monolayers studied in Ussing chambers displayed constitutive and forskolin stimulated chloride currents, which may be attributed to the enhanced transepithelial electrochemical gradient generated by activation of basolateral potassium channels by cAMP/PKA signaling ([@B48]; [@B60]). Moreover, studies in primary human bronchial epithelial (HBE) cells elegantly demonstrated the presence of a SLC26A9-mediated transepithelial chloride conductance, which contributed to basal and to cAMP/PKA stimulated chloride currents ([@B12], [@B11]). These finding support that SLC26A9 could provide an alternative pathway for chloride secretion that may compensate for CFTR dysfunction in CF epithelia. In addition, several studies suggested that SLC26A9 also functions as a chloride-bicarbonate exchanger ([@B73]; [@B19]; [@B26]) and sodium transporter ([@B19]). However, the contribution of SLC26A9 to epithelial bicarbonate and sodium transport is not completely understood (see discussion at stomach) and it is possible that transport modes depend on the cell and tissue context.

In the absence of sensitive and specific antibodies for immunolocalization studies, investigations of SLC26A9 largely relied on pharmacological tools. Multiple compounds were found to inhibit SLC26A9 at various potency and selectivity. Highly effective inhibitors include several non-selective chloride channel blockers, such as flufenamic acid, niflumic acid, GlyH-101, and 5-Nitro-2-(3-phenylpropylamino)benzoic acid (NPPB), while anion-exchanger inhibitor 4,4′-Diisothiocyanatostilbene-2,2′-disulfonic acid (DIDS) only partially inhibited SLC26A9 ([@B27]; [@B46]; [@B60]). On the other hand, SLC26A9 is not sensitive to diphenylamine-2-carboxylic acid (DPC), glibenclamide or CFTRinh172, which makes differentiation from CFTR-mediated chloride currents possible ([@B46]; [@B12]; [@B60]). Despite the lack of highly selective inhibitors, this characteristic "pharmacological fingerprint" enabled investigation of SLC26A9-mediated chloride secretion in primary epithelial cultures and native tissues ([@B3]; [@B11]).

The constitutive channel activity suggests that SLC26A9-mediated chloride secretion is controlled by the insertion and stability of SLC26A9 channels in the plasma membrane. Previous studies demonstrated that SLC26A9 cell surface expression is influenced by WNK (with no lysine \[K\]) kinases that have been implicated in the regulation of cell volume homeostasis and ion transport processes in epithelial cells ([@B27]; [@B60]). WNK kinases uniquely function as intracellular chloride and/or osmolality sensors that activate downstream kinases serine/threonine-protein kinase 39 (SPAK) and oxidative stress-responsive 1 protein (OSR1), which can directly modulate ion transporters by phosphorylation ([@B1]; [@B8]). Furthermore, WNKs can also act as scaffolds that recruit other proteins that regulate the activity or plasma membrane abundance of ion channels ([@B57]). This kinase-independent function of WNKs has been demonstrated to affect plasma membrane trafficking of SLC26A9, as well as CFTR, by mechanisms that may involve lysosomal targeting or endosomal sorting ([@B27]; [@B32]; [@B75]; [@B76]).

Notably, there is a large overlap in the expression pattern of SLC26A9 and CFTR in epithelial tissues and emerging evidence suggests a complex, multifaceted interaction between the two channels, both under physiological and pathophysiological conditions. First, there is a functional interaction between the two channels mediated by the STAS domain of SLC26A9 and the R domain of CFTR. Although an inhibitory relationship has also been suggested ([@B18]), the nature of this molecular interaction is likely stimulatory, as SLC26A9 contributes to cAMP-stimulated chloride currents in HBE cells and co-expression of CFTR with SLC26A9 results in larger chloride currents than expression of CFTR alone ([@B46]; [@B5]). Interestingly, the cellular background and level of differentiation may be important determinants of this functional interaction between SLC26A9 and CFTR, as suggested by a study that showed a different behavior in human embryonic kidney (HEK293) cells compared to polarized airway epithelial cells ([@B53]). Of note, opposite functional interactions between CFTR and SLC26A9 were also reported in two heterologous expression studies that both used HEK cells ([@B12]; [@B53]). While these conflicting results are more difficult to reconcile, we speculate that the observed differences in CFTR/SLC26A9 interactions may be related to differences in the cellular background of the HEK cell clones used in the different laboratories.

Biochemical and functional studies of two other SLC26 family members, SLC26A6 and SLC26A3, showed that following cAMP-dependent stimulation, the phosphorylated R domain can bind to STAS domain, which leads to mutual activation of both CFTR and SLC26 transporters ([@B36]). Coding mutations located in the STAS domain of SLC26A9 may disrupt this stimulatory interaction, as demonstrated by functional analysis of variant L683P ([@B4]). Interestingly, STAS domain variant V622L and domain adjacent variant V744M decreased chloride currents of SLC26A9, which could be partially attributed to decreased plasma membrane expression ([@B20]). Although no disease-association has been reported for the variants above, these studies demonstrate the role of SLC26A9 STAS domain in protein expression, channel function, and stimulation of CFTR currents.

Second, a recent study demonstrated a physical interaction between SLC26A9 and CFTR, which is mediated by PDZ proteins that facilitate trafficking and stabilization of both proteins at the cell surface ([@B11]). As shown by co-localization studies, this interaction is not restricted to the plasma membrane suggesting a common regulatory mechanism along the secretory pathway ([@B5]; [@B11]). SLC26A9 shows affinity to a number of PDZ proteins, such as Na^+^/H^+^ exchanger-3 regulatory factor 1 (NHERF1) and CFTR-associated ligand (CAL), which display antagonistic effects in CFTR trafficking ([@B11]). CAL, also known as GOPC (Golgi-associated PDZ and coiled-coil motif-containing protein) facilitates ubiquitination and lysosomal degradation of CFTR, as well as endoplasmic reticulum (ER)-associated degradation of F508del-CFTR, whereas NHERF1 tethers CFTR to the plasma membrane thus promoting its cell surface expression ([@B21]; [@B9]). Moreover, F508del-CFTR could be rescued by NHERF1 overexpression or CAL silencing ([@B71]; [@B17]). Constitutive SLC26A9-mediated chloride secretion is diminished in human bronchial epithelium from CF donors carrying F508del-CFTR and recent evidence suggests a PDZ-domain sensitive, CAL-dependent underlying mechanism ([@B12], [@B11]). Due to proteasomal degradation of F508del-CFTR, association of CAL with SLC26A9 increases, which in turn hampers its forward trafficking. Furthermore, restoration of F508del-CFTR by the small molecule CFTR corrector compound VX-809 increased CFTR as well as SLC26A9 cell surface expression indicating that rescue of intracellular processing of CFTR has a positive influence on SLC26A9 membrane targeting. Consistent with this notion, SLC26A9-mediated chloride currents were not affected by co-expression with the CFTR gating mutation G551D, which is inserted into the plasma membrane, but has impaired CFTR chloride channel regulation ([@B11]).

Third, numerous genetic association studies and investigations utilizing genetically modified mouse models supported an important role of SLC26A9 in the pathophysiology of several organ manifestations in CF, as well as other chronic lung diseases such as asthma and non-CF bronchiectasis ([@B3]; [@B67]; [@B6]; [@B13]; [@B51]; [@B66]). The results of these studies are consistent with an important role of SLC26A9 as a disease modifier in CF and potentially other muco-obstructive lung diseases and are discussed in more detail below (**Figure [1](#F1){ref-type="fig"}**).

![SLC26A9 is a modifier of disease severity in multiple organs affected by CF. Graphical summary depicting associations of variants in *SLC26A9* with exocrine pancreatic insufficiency, CF-related diabetes mellitus (CFRD) and meconium ileus, and emerging data supporting a role of SLC26A9 as modifier of response to CFTR modulator therapy in patients with CF. Beyond CF, SLC26A9 has been implicated in the pathogenesis of asthma, diffuse bronchiectasis (DB), and impaired gastric acid secretion.](fphar-09-01112-g001){#F1}

SLC26A9 Chloride Channel as a Disease Modifier in CF
====================================================

Lung
----

Muco-obstructive lung disease remains the major cause of morbidity and mortality in patients with CF. The basic CF ion transport defect causes airway surface dehydration, impaired mucociliary clearance and mucus obstruction, which triggers chronic inflammation and infection, and ultimately leads to progressive lung damage ([@B16]). There is a large heterogeneity in lung disease severity among CF patients, which is influenced by genetic and environmental factors. It is estimated that ∼50% of the genetically determined variability can be attributed to the CFTR genotype and the other ∼50% to CF modifier genes ([@B24]). In an effort to identify genetic determinants of CF lung disease, genome-wide association studies (GWAS) were performed in large CF patient cohorts ([@B72]; [@B23]). These studies revealed a number of loci and candidate genes that may influence lung function, but initially, these investigations did not find association with SLC26A9. However, more recently, SLC26A9 was reported as a modifier of lung function and response to CFTR modulator therapy in patients carrying the CFTR gating mutation G551D ([@B66]). In a cohort of over 1,700 F508del homozygous CF patients and 70 patients with at least one G551D allele the authors examined the effect of SLC26A9 SNP rs7512462, which was previously reported to associate with CF related diabetes, pancreatic insufficiency and meconium ileus. The minor C allele of rs7512462 positively influenced lung function in G551D CF patients, but had no effect in F508del homozygotes. Furthermore, improvement of lung function, as determined from FEV1 response to therapy with the small molecule CFTR potentiator ivacaftor (VX-770) was markedly higher in patients carrying at least one protective C allele. This study also assessed the effect of rs7512462 in primary HBE cultures from F508del homozygous CF patients and found that rescue of cAMP-stimulated currents in cultures pretreated with lumacaftor (VX-809) increased with each additional C allele ([@B66]). In the presence of an *in vitro* modulatory effect, the lack of SLC26A9 association with lung function in F508del homozygous patients is difficult to reconcile. One explanation may entail the F508del dependent trafficking defect of SLC26A9 and the necessity of CFTR plasma membrane targeting for SLC26A9 function discussed above ([@B11]). On the other hand, age-dependent expression may also be involved. Interestingly, a recent study in a Brazilian cohort of 188 CF patients revealed association of rs7512462 with several outcome measures of pulmonary function ([@B55]). Taken together, these data support that SLC26A9 is a modulator of response to CFTR targeted therapies, which in the future may help predict patient outcomes and optimize tailored treatment regimens for individual patients with CF.

Idiopathic diffuse bronchiectasis (DB) is a chronic lung disease involving airway mucus obstruction, recurrent infections, airway inflammation, and remodeling that resembles CF lung disease in many aspects ([@B10]). Interestingly, a previous study reported rare loss-of-function SLC26A9 mutations in patients with DB suggesting that SLC26A9 may be implicated in disease pathogenesis. In a study comparing 147 patients with DB, 78 patients with CF and 50 healthy controls, exon sequencing of SLC26A9 revealed coding variants R575Y and V486I in two DB patients ([@B6]). Functional analysis showed that both mutations abolished chloride currents and that R575Y located in the STAS domain also interfered with the stimulatory interaction with CFTR.

Further insights on the importance of SLC26A9 in airway epithelial chloride secretion, airway surface hydration, and mucus clearance came from studies in mice with allergic airway disease. In a murine model of allergic asthma, it was shown that type 2 airway inflammation induced SLC26A9-mediated Cl^−^ secretion, which prevented airway mucus plugging in presence of mucus hypersecretion ([@B2], [@B3]). In the absence of allergic airway inflammation, *Slc26a9*-deficient (*Slc26a9*^−/−^) mice displayed normal lung morphology and no differences in epithelial ion transport when compared to wild-type mice. However, in the presence of allergic inflammation *Slc26a9*^−/−^ mice lacked upregulation of chloride secretion and mucus hypersecretion led to airway mucus plugging. Furthermore, three SNPs at 3′ UTR of SLC26A9 were identified that were associated with a risk for childhood asthma, with an odds ratio of 1.48. Functional investigations revealed that one of these non-coding variants altered a putative micro-RNA response element in the 3′ UTR of SLC26A9 and lead to micro-RNA mediated translational repression *in vitro*, indicating that decreased SLC26A9 protein expression may be the underlying mechanism for disease association ([@B3]).

Stomach
-------

Investigations in the stomach revealed an essential role of SLC26A9 in the regulation of gastric acid secretion. In the gastric mucosa SLC26A9 is expressed in the surface epithelial cells and in the parietal cells of the deep gastric gland. *Slc26a9*^−/−^ mice displayed structural and ultrastructural changes, such as distended gastric glands, hypoplasia of parietal cells, and loss of tubulovesicular system inside the parietal cells ([@B74]). Furthermore, H-K-ATPase expression was decreased. *Slc26a9^−/−^* mice had complete achlorhydria, which could be explained by the absence of transmucosal chloride secretion and/or the role of Slc26a9 in the maintenance and maturation of the secretory pathway that regulates the H-K-ATPase trafficking. Alternatively, Slc26a9 could also promote gastric bicarbonate secretion and regulation of luminal pH to protect against injury by gastric acid ([@B73]; [@B26]). It is currently debated how SLC26A9 could contribute to bicarbonate secretion. One possibility would be that SLC26A9-mediated chloride secretion is paralleled by chloride-bicarbonate exchange via apical anion exchangers, similarly to the proposed model of pancreatic fluid secretion, where CFTR works tandem with anion exchangers to secrete bicarbonate ([@B65]). The second possibility is that SLC26A9 itself can operate as an anion exchanger, which was supported by two studies on gastric epithelium ([@B73]; [@B26]), however, most heterologous expression data suggest that SLC26A9 functions as an ion channel with minimal bicarbonate conductance. Third, the channel conductance to bicarbonate could also be modulated, similarly to the regulation of CFTR bicarbonate permeability by WNK1-OSR1/SPAK pathway ([@B54]). Notably, SLC26A9 expression was upregulated in *Helicobacter pylori* infection, as well as upon chronic gastritis induced by interleukin-11 in mice, indicating that SLC26A9 is a key player in gastric mucosal defense under pathological conditions ([@B33]; [@B35]).

Intestine
---------

Obstruction of the ileum due to highly viscous and sticky bowel content, also known as meconium ileus, affects ∼15% of newborns with CF. Sibling and twin studies demonstrated a high heritability for this disease phenotype and a number of genetic studies reported association of SLC26A9 with meconium ileus ([@B14]; [@B67]; [@B42]; [@B51]). SLC26A9 expression decreases along the GI tract with relatively high levels in the stomach, medium levels in the proximal duodenum, low levels in the ileum and no detectable expression in the colon, whereas CFTR shows an inverse pattern with low expression in the stomach and high levels in the duodenum, small intestine and colon ([@B43]). *Cftr*-deficient (*Cftr^−/−^*) mice show a severe meconium ileus-like intestinal phenotype characterized by severe intestinal plugging. When *Cftr^−/−^* mice were crossbred with *Slc26a9^−/−^* mice, mortality highly increased, indicating that SLC26A9-mediated anion secretion ameliorates meconium ileus ([@B43]). *Slc26a9^−/−^* mice also failed to elicit duodenal bicarbonate secretion in response to acid load, which may signify the physiological role of SLC26A9 to neutralize gastric acid in the duodenum ([@B62]).

Pancreas
--------

Exocrine pancreatic insufficiency (PI) in CF is present from early life in nearly all patients with severe CFTR genotypes. CFTR is expressed in the pancreatic ductal epithelium and regulates the secretion of an alkaline, bicarbonate rich pancreatic fluid that washes out digestive enzymes produced by acinar cells. CFTR dysfunction leads to an acidic, low volume, protein rich secretion that can slow down or even block the outflow of zymogens from the ductal tree ([@B37]). Early histopathological changes include dilatation of ducts filled with inspissated zymogen material and destruction of acinar cells ([@B69]). In advanced stages, fibrotic and adipose tissue replaces acinar mass and destroys Langerhans-islands ([@B30]). PI shows a strong, but incomplete correlation with CF genotype and CFTR chloride channel function, while SLC26A9 can largely explain the remainder of genetic variability ([@B25]; [@B34]; [@B42]; [@B51]). These studies found correlation between circulating levels of immunoreactive trypsinogen (IRT), an early biomarker for exocrine damage, and SLC26A9 SNPs that also associated with meconium ileus and CF-related diabetes mellitus (CFRD). The physiological function of SLC26A9 in the pancreas is largely unexplored. Emerging data suggest that SLC26A9 may enhance ductal anion transport and fluid secretion ([@B41]). Impaired SLC26A9-mediated secretion may thus aggravate the defective ductal wash-out mechanism and ductal plugging in CF. Reduced fluid secretion and ductal mucus obstruction are also present in chronic pancreatitis, a disease that shares many key pathogenic features with CF of the pancreas ([@B47]; [@B7]). It is conceivable that SLC26A9 may also act as a modifier in these disorders.

Pancreatic insufficiency confers a major risk for CFRD. CFRD is an age-dependent complication that affects 2% of children and 50% of adults with high heritability ([@B15]; [@B52]). A GWAS identified major association of SLC26A9 variants with CFRD, with a hazards ratio of 1.47. Interestingly, meta-analysis of two GWAS studies in type II diabetes showed evidence for association with the same SLC26A9 SNPs, although the risk allele was different ([@B13]). There are two prevailing hypotheses on CFRD development: one is that CFRD is driven by the exocrine damage that stresses endocrine cells and causes islet remodeling ([@B59]). This is supported by a Mendelian randomization study utilizing a disease-associated SLC26A9 SNP, where a causal relationship between PI and CFRD risk was determined ([@B63]). Alternatively, loss of CFTR function might have a direct role in insulin secretion ([@B31]) and/or result in an intrinsic defect that impairs endocrine function before acinar damage occurs ([@B30]). Given its function as chloride channel, it is possible that SLC26A9 may regulate membrane potential and insulin secretion in β-cells, however, there are no data available that support expression of SLC26A9 in the endocrine pancreas.

Conclusion and Future Directions
================================

In summary, SLC26A9 constitutes an alternative chloride channel that is implicated in coordinated ion and fluid secretion in various epithelial tissues affected in CF including the airways, the pancreas and the gastro-intestinal tract ([@B44]; [@B27]; [@B12]). Demonstration of its role as a disease modifier, as well as overlapping expression of SLC26A9 and CFTR in several affected organs, suggest SLC26A9 as an attractive alternative therapeutic target to bypass the primary ion transport defect in CF ([@B67]; [@B13]; [@B51]; [@B66]). In the airways, activation of SLC26A9-mediated chloride/fluid secretion is predicted to counteract airway surface dehydration that sets the stage for mucus plugging and mucociliary dysfunction and constitutes an important disease mechanism in CF lung disease ([@B50]). Similarly, in the gastro-intestinal tract, activation of SLC26A9 chloride channels is expected to improve the hydration of intestinal surfaces and facilitate pancreatic fluid secretion thus counteracting important extra-pulmonary organ dysfunctions in CF. Therefore, SLC26A9 is an attractive target not only for the treatment of CF lung disease, but also for systemic therapy that may be beneficial for the prevention and/or treatment of several extrapulmonary disease manifestations including meconium ileus and distal intestinal obstruction syndrome (DIOS), exocrine pancreatic insufficiency and CFRD. Further, pharmacological activation of SLC26A9-mediated chloride/fluid secretion may also be beneficial in other muco-obstructive lung diseases and in chronic pancreatitis ([@B49]; [@B7]). Importantly activation of an alternative chloride channel is expected to be beneficial for all patients with CF, irrespective of their *CFTR* genotype, including patients with non-sense or splicing mutations, where no CFTR protein is made, or other rare CFTR mutations that do not respond to emerging CFTR modulator therapies ([@B39]). Given the reciprocal interaction with CFTR (**Figures [2A--C](#F2){ref-type="fig"}**), pharmacological activation of SLC26A9 may also augment functional rescue of mutant CFTR achieved by CFTR modulator therapies ([@B66]; [@B11]). However, to date, no compounds that activate SLC26A9 chloride channel function have been reported and the development of such SLC26A9 modulators remains a major challenge for further testing of these concepts in preclinical models and in the clinical arena. In this context, the negative impact of the common CFTR mutation F508del present on at least one allele in ∼90% of CF patients on SLC26A9 trafficking indicates that an ideal SLC26A9 modulator compound should overcome this interaction and facilitate trafficking of SLC26A9 from the ER to the plasma membrane independent of CFTR co-trafficking ([@B66]; [@B11]; **Figure [2D](#F2){ref-type="fig"}**). In addition to compounds that facilitate SLC26A9 trafficking to increase the number of channels, SLC26A9-mediated chloride secretion may be augmented by compounds that enhance the open probability of the channel or its stability in the plasma membrane. Single channel recordings demonstrated SLC26A9 channels with open and closed states and a conductance of ∼3.2 pS ([@B19]) suggesting that it may be possible to increase the open probability by SLC26A9 potentiator compounds. Taking the development of CFTR modulators as a model for drug development, such SCL26A9 modulators may be identified by high-throughput screening of compound libraries in SLC26A9-expression epithelial cells ([@B29]). In addition, a better understanding of SLC26A9 regulation in epithelial tissues, including its interaction network and signaling pathways, may help to explore SLC26A9 as a novel therapeutic target in CF and potentially other muco-obstructive lung diseases.

![Role SLC26A9 in healthy airways and as a therapeutic target in cystic fibrosis (CF). Healthy airway epithelia express SLC26A9 and CFTR that are co-trafficked from the ER to the plasma membrane, where SLC26A9 functions as a constitutive and CFTR as a cAMP/PKA-regulated chloride channel. Further, SLC26A9 and CFTR interact reciprocally to augment transepithelial chloride/fluid secretion essential to maintain proper airway surface hydration and effective mucociliary clearance **(A)**. In airway epithelial cells from patients with CF carrying the most common disease-causing mutation F508del-CFTR, impaired folding of F508del leads to its retention in the ER and degradation by the proteasome. The F508del trafficking defect also hampers co-trafficking of SLC26A9 and its insertion into the plasma membrane. Lack of SLC26A9 chloride channels may aggravate deficient chloride secretion in CF **(B)**. Pharmacological rescue of F508del-CFTR trafficking with the CFTR corrector lumacaftor (VX-809) restores co-trafficking and insertion of SLC26A9 chloride channels into the apical plasma membrane **(C)**. Compounds that facilitate trafficking of SLC26A9 in the absence of CFTR may improve chloride secretion and airway surface hydration in all patients with CF regardless of the type of CFTR mutation. Alternatively, chloride secretion may also be facilitated by compounds that potentiate SLC26A9 channels that are present and/or newly trafficked to the plasma membrane **(D)**.](fphar-09-01112-g002){#F2}
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